These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
146 related articles for article (PubMed ID: 24347509)
1. A chemotherapy only therapeutic approach to pediatric Hodgkin lymphoma: AHOPCA LH 1999. Castellanos EM; Barrantes JC; Báez LF; Gamboa Y; Peña A; Alabi S; Bonilla M; Wang H; Metzger ML; de Alarcón PA Pediatr Blood Cancer; 2014 Jun; 61(6):997-1002. PubMed ID: 24347509 [TBL] [Abstract][Full Text] [Related]
2. Treatment of childhood Hodgkin's disease with COPP or COPP-ABV (hybrid) without radiotherapy in Nicaragua. Baez F; Ocampo E; Conter V; Flores A; Gutierrez T; Malta A; Pacheco C; Palacios R; Biondi A; Riva L; Sala A; Silvestri D; Cavalli F; Sessa C; Casanova M; Masera G Ann Oncol; 1997 Mar; 8(3):247-50. PubMed ID: 9137793 [TBL] [Abstract][Full Text] [Related]
3. Treatment of pediatric Hodgkin's disease with chemotherapy alone or combined modality therapy. Muwakkit S; Geara F; Nabbout B; Farah RA; Shabb NS; Hajjar T; Khogali M Radiat Oncol Investig; 1999; 7(6):365-73. PubMed ID: 10644060 [TBL] [Abstract][Full Text] [Related]
4. Combined-modality therapy for clinical stage I or II Hodgkin's lymphoma: long-term results of the European Organisation for Research and Treatment of Cancer H7 randomized controlled trials. Noordijk EM; Carde P; Dupouy N; Hagenbeek A; Krol AD; Kluin-Nelemans JC; Tirelli U; Monconduit M; Thomas J; Eghbali H; Aleman BM; Bosq J; Vovk M; Verschueren TA; Pény AM; Girinsky T; Raemaekers JM; Henry-Amar M J Clin Oncol; 2006 Jul; 24(19):3128-35. PubMed ID: 16754934 [TBL] [Abstract][Full Text] [Related]
5. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. Diehl V; Franklin J; Pfreundschuh M; Lathan B; Paulus U; Hasenclever D; Tesch H; Herrmann R; Dörken B; Müller-Hermelink HK; Dühmke E; Loeffler M; N Engl J Med; 2003 Jun; 348(24):2386-95. PubMed ID: 12802024 [TBL] [Abstract][Full Text] [Related]
6. Hybrid chemotherapy consisting of cyclophosphamide, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, and vinblastine (C-MOPP/ABV) as first-line treatment for patients with advanced Hodgkin disease. Montoto S; Camós M; López-Guillermo A; Bosch F; Cervantes F; Blandé J; Esteve J; Cobo F; Nomdedeu B; Campo E; Montserrat E Cancer; 2000 May; 88(9):2142-8. PubMed ID: 10813727 [TBL] [Abstract][Full Text] [Related]
7. Stage-adapted treatment of HIV-associated Hodgkin lymphoma: results of a prospective multicenter study. Hentrich M; Berger M; Wyen C; Siehl J; Rockstroh JK; Müller M; Fätkenheuer G; Seidel E; Nickelsen M; Wolf T; Rieke A; Schürmann D; Schmidmaier R; Planker M; Alt J; Mosthaf F; Engert A; Arasteh K; Hoffmann C J Clin Oncol; 2012 Nov; 30(33):4117-23. PubMed ID: 23045592 [TBL] [Abstract][Full Text] [Related]
8. Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease. Fermé C; Eghbali H; Meerwaldt JH; Rieux C; Bosq J; Berger F; Girinsky T; Brice P; van't Veer MB; Walewski JA; Lederlin P; Tirelli U; Carde P; Van den Neste E; Gyan E; Monconduit M; Diviné M; Raemaekers JM; Salles G; Noordijk EM; Creemers GJ; Gabarre J; Hagenbeek A; Reman O; Blanc M; Thomas J; Vié B; Kluin-Nelemans JC; Viseu F; Baars JW; Poortmans P; Lugtenburg PJ; Carrie C; Jaubert J; Henry-Amar M; N Engl J Med; 2007 Nov; 357(19):1916-27. PubMed ID: 17989384 [TBL] [Abstract][Full Text] [Related]
9. Pediatric Hodgkin's disease. Oliapuram Jose B; Koerner P; Bertolone S; Patel CC; Spanos WJ; Paris KJ; Silverman CL; Yashar CM J Ky Med Assoc; 2004 Mar; 102(3):104-6. PubMed ID: 15067795 [TBL] [Abstract][Full Text] [Related]
10. [Treatment results and prognostic significance of selected clinical and laboratory features in children diagnosed with malignant lymphoma]. Kamieńska E Ann Acad Med Stetin; 1996; 42():105-22. PubMed ID: 9199116 [TBL] [Abstract][Full Text] [Related]
11. Survival and late effects in children with Hodgkin's lymphoma treated with MOPP/ABV and low-dose, extended-field irradiation. Chow LM; Nathan PC; Hodgson DC; Jenkin D; Weitzman S; Grant RM; Manson D; Bross A; Doyle JJ; Danjoux C; Greenberg ML J Clin Oncol; 2006 Dec; 24(36):5735-41. PubMed ID: 17179107 [TBL] [Abstract][Full Text] [Related]
12. Radiotherapy of early stages Hodgkin's disease. 10 years experience of the Masaryk Memorial Cancer Institute. Petera J; Macharová H; Pohanková R; Malír A; Coupek P; Konecný M; Patera J; Pecina J; Drbal J; Koukalová H; Vásová I Neoplasma; 2000; 47(2):129-32. PubMed ID: 10985481 [TBL] [Abstract][Full Text] [Related]
13. Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin's lymphoma: results of the HD8 trial of the German Hodgkin's Lymphoma Study Group. Engert A; Schiller P; Josting A; Herrmann R; Koch P; Sieber M; Boissevain F; De Wit M; Mezger J; Duhmke E; Willich N; Muller RP; Schmidt BF; Renner H; Muller-Hermelink HK; Pfistner B; Wolf J; Hasenclever D; Loffler M; Diehl V; J Clin Oncol; 2003 Oct; 21(19):3601-8. PubMed ID: 12913100 [TBL] [Abstract][Full Text] [Related]
14. Biophysical analysis of the acute toxicity of radiotherapy in Hodgkin's lymphoma--a comparison between extended field and involved field radiotherapy based on the data of the German Hodgkin Study Group. Eich HT; Haverkamp U; Engert A; Kocher M; Skripnitchenko R; Brillant C; Sehlen S; Dühmke E; Diehl V; Müller RP Int J Radiat Oncol Biol Phys; 2005 Nov; 63(3):860-5. PubMed ID: 15925455 [TBL] [Abstract][Full Text] [Related]
15. Treatment of high-risk Hodgkin lymphoma with a modified Stanford V regimen in the AHOPCA: Substituting chemotherapy agents and hampered outcomes. Luna-Fineman S; Castellanos M; Metzger ML; Baez LF; Peña Hernandez A; Bonilla M; Fuentes-Alabi S; Nieves R; Blanco J; Rossi E; Devidas M; Chen Y; Arreola M; de Alarcon PA Pediatr Blood Cancer; 2024 Feb; 71(2):e30792. PubMed ID: 38053237 [TBL] [Abstract][Full Text] [Related]
16. Comparison of treatment outcomes of childhood Hodgkin lymphoma in two US centers and a center in Recife, Brazil. Hsu SC; Metzger ML; Hudson MM; Pedrosa F; Lins M; Pedrosa M; Barros C; Maciel K; Pui CH; Ribeiro RC; Howard SC Pediatr Blood Cancer; 2007 Aug; 49(2):139-44. PubMed ID: 16642484 [TBL] [Abstract][Full Text] [Related]
17. Improving the prognosis of pediatric Hodgkin lymphoma in developing countries: a Moroccan Society of Pediatric Hematology and Oncology study. Hessissen L; Khtar R; Madani A; El Kababri M; Kili A; Harif M; Khattab M; Sahraoui S; Benjaafar N; Ahid S; Howard SC; Benchekroun S Pediatr Blood Cancer; 2013 Sep; 60(9):1464-9. PubMed ID: 23606223 [TBL] [Abstract][Full Text] [Related]
18. Survival improvement of young patients, aged 16-23, with Hodgkin lymphoma (HL) during the last three decades. Koumarianou AA; Xiros N; Papageorgiou E; Pectasides D; Economopoulos T Anticancer Res; 2007; 27(2):1191-7. PubMed ID: 17465262 [TBL] [Abstract][Full Text] [Related]
19. Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study. Engert A; Diehl V; Franklin J; Lohri A; Dörken B; Ludwig WD; Koch P; Hänel M; Pfreundschuh M; Wilhelm M; Trümper L; Aulitzky WE; Bentz M; Rummel M; Sezer O; Müller-Hermelink HK; Hasenclever D; Löffler M J Clin Oncol; 2009 Sep; 27(27):4548-54. PubMed ID: 19704068 [TBL] [Abstract][Full Text] [Related]
20. Treatment of children and adolescents with Hodgkin lymphoma without radiotherapy for patients in complete remission after chemotherapy: final results of the multinational trial GPOH-HD95. Dörffel W; Rühl U; Lüders H; Claviez A; Albrecht M; Bökkerink J; Holte H; Karlen J; Mann G; Marciniak H; Niggli F; Schmiegelow K; Schwarze EW; Pötter R; Wickmann L; Schellong G J Clin Oncol; 2013 Apr; 31(12):1562-8. PubMed ID: 23509321 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]